尽管净利和ROE均为负数,但Twist Bioscience报告第二季度收入增长了27.7%. Twist Bioscience reports Q2 revenue increase of 27.7%, despite negative net margin and ROE.

合成DNA制造商Twist Bioscience获得了八位分析师的"中等购买"评级, Twist Bioscience, a synthetic DNA manufacturer, holds a "Moderate Buy" rating from eight analysts with an average one-year price target of $51.63. 诸如TD Cowen(65美元)和Goldman Sachs(55美元)等公司提出了价格目标。 Price targets have been raised by firms like TD Cowen ($65) and Goldman Sachs ($55). 尽管净利率为74.63%和股权回报率为-32.17%,但该公司在第二季度的收入增长了27.7%,总计为8150万美元. Despite a negative net margin of 74.63% and return on equity of -32.17%, the company reported a 27.7% revenue increase in Q2, totaling $81.5 million. 内部销售已经发生,注意到大量机构投资。 Insider sales have occurred, with significant institutional investments noted.